HEALTH-RELATED QUALITY OF LIFE RESULTS FROM THE RANDOMIZED PHASE II TAVAREC TRIAL ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB IN 1p/19q INTACT FIRS RECURRENCE WHO GRADE II AND III GLIOMA (EORTC 26091)
Author(s):
Reijneveld, J.C.; Coens, C.; Taphoorn, M.J.B.; Smitt, P.S.; Clement, P.M.; Idbaih, A.; Vos, F. de; Klein, M.; Wick, W.G.; Mulholland, P.; Lewis, J.; Golfinopoulos, V.; Bottomley, A.; Bent, M. van den
